Allelix Biopharmaceuticals Inc. announced that it has receivedapproval from the Canadian government to proceed withhuman clinical trials of its drug for treating HIV infection.Allelix, based in Toronto, plans to begin the Phase I trial inOctober.

The company's (TSE:AXB) drug ALX40-4C inhibits HIVreplication by interfering with the viral process oftransactivation. Specifically, the drug blocks the binding of theviral protein TAT (transactivator) to the viral RNA structuretermed TAR (transactivation response) by binding to the TARstructure itself. This effectively prevents transactivation andsubsequent viral replication.

ALX40-4C is the first drug from Allelix's research program ingene or transcription targeted pharmaceuticals to enter clinicaltrials.

(c) 1997 American Health Consultants. All rights reserved.